Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Capital Expenditures (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Capital Expenditures for 7 consecutive years, with $106000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 88.68% to $106000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, down 88.71% year-over-year, with the annual reading at $1.4 million for FY2025, 88.71% down from the prior year.
  • Capital Expenditures for Q4 2025 was $106000.0 at Kymera Therapeutics, down from $181000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $11.6 million in Q4 2023, with the low at -$189000.0 in Q3 2024.
  • Average Capital Expenditures over 5 years is $2.7 million, with a median of $660500.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures skyrocketed 3016.62% in 2023, then crashed 102.34% in 2024.
  • Over 5 years, Capital Expenditures stood at $501000.0 in 2021, then decreased by 25.55% to $373000.0 in 2022, then surged by 3016.62% to $11.6 million in 2023, then plummeted by 91.95% to $936000.0 in 2024, then plummeted by 88.68% to $106000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $106000.0, $181000.0, and $695000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.